Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...

Hutchins Academy announces that Va'niyah Hoxie, a senior at East Hamilton and Hutchins Academy mentee, has secured a $26,895 ...

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. It is the first and only PD-L1 blocker approved to treat ...

Greta Shudan, of Chattanooga, has been named to the Provost's List at Troy University for the Fall Semester/Term 2 of the 2024-2025 academic year. The Provost's List honors full-time undergraduate ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.